Objective:To summarize and compare the clinical characteristics of immune checkpoint inhibitor-associated pneumonia(CIP)in elderly and non-elderly lung cancer patients treated with immune checkpoint inhibitors(ICIs).Methods:We conducted a retrospective analysis of the clinical data from 61 patients who developed CIP following ICIs treatment in the Respiratory and Critical Care Medicine Department and the Oncology Department of Beijing Hospital from May 2016 to April 2024.The clinical characteristics of patients aged 65 years and older were compared with those of patients younger than 65 years.Results:A total of 61 patients were included in the study, with 26 patients in the group aged <65 years[aged 39-64(56.3±5.6)years].Within this group, the clinical grades were distributed as follows: 5 patients in grade 1(G1), 12 in grade 2(G2), 7 in grade 3(G3), and 2 in grade 4(G4).Twelve patients underwent bronchoscopy, while 17 patients received corticosteroid therapy after developing CIP.Additionally, 20 patients permanently discontinued immunotherapy due to CIP.Notably, one patient showed improvement in CIP following treatment, which allowed for the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.In the group aged ≥65 years[aged 65-83(71.9±4.9)years], there were 35 patients, categorized as follows: 4 in G1, 22 in G2, 5 in G3, and 4 in G4.Twenty-one patients underwent bronchoscopy, 31 received corticosteroid therapy after developing CIP, and 30 patients permanently discontinued immunotherapy due to CIP.Similarly, one patient in this group demonstrated improvement in CIP following treatment, which permitted the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.Compared to patients aged <65 years, those aged ≥65 years experienced a shorter median time to the occurrence of CIP, with a median of 2(1, 4)months versus 5.5(2, 8)months for the younger group( Z=-3.231, P=0.001).Furthermore, a higher proportion of patients aged ≥65 years received corticosteroid therapy after developing CIP(88.57% or 31 cases)compared to 65.38%(17 cases)in the younger group( χ2=4.704, P=0.030).There were no statistically significant differences in the occurrence of CIP symptoms or chest imaging characteristics between the two age groups(both P>0.05). Conclusions:Patients aged 65 years and older experience a shorter median time to develop CIP following the use of ICIs.However, there is no significant difference in clinical outcomes when compared to the group aged under 65 years, provided that early identification and diagnosis are achieved.

Objective:To summarize the clinical characteristics of SAPHO syndrome in elderly patients with organizing pneumonia.Methods:We reported a case of SAPHO syndrome in an elderly patient with organizing pneumonia.Relevant reports on SAPHO syndrome with organizing pneumonia at home and abroad were retrieved, and the literature was summarized an analyzed.Results:The patient was a 63-year-od female who was admitted to the hospital due to "intermittent fever and cough for more than two months". Before admission, she was previously diagnosed with pneumonia in another hospital with poor response to anti-infective treatment.Chest CT showed multiple bilateral patchy consolidations in both lungs, with migratory changes and reversed halo signs.Her medical history included bone and joint pain(e.g., sternoclavicular joints)and palmoplantar pustulosis.Lung biopsy pathology confirmed organizing pneumonia. 99mTc-MDP bone scintigraphy revealed abnormal bone salt metabolism in multiple bone and joint areas.The final diagnosis was SAPHO syndrome with organizing pneumonia.Both symptoms and imaging significantly improved after prednisone treatment.Two related cases were retrieved from the literature.One was a 57-year-old female reported in the UK, who had been diagnosed with SAPHO syndrome before and was found to have lung consolidations due to respiratory symptoms.Lung biopsy confirmed organizing pneumonia, and she improved after glucocorticoid treatment.The other was a 59-year-old Chinese female who visited hospital due to pain in the lumbosacral part and left lower limb.After being diagnosed with SAPHO syndrome, a chest CT scan was performed and lung consolidations were found.The pathology confirmed organizing pneumonia.The patient improved after treatment with Tripterygium wilfordii. Conclusion:SAPHO syndrome complicated with organizing pneumonia is rare, with diverse clinical manifestations, and responds well to glucocorticoid therapy.

Objective:To evaluate the clinical efficacy of total thoracoscopic mitral valve surgery combined with beating-heart tricuspid valvuloplasty under the concept of enhanced recovery after surgery (ERAS).Methods:Clinical data from the People′s Hospital of Guangxi Zhuang Autonomous Region from January 2012 to January 2024 were collected and analyzed retrospectively. Patients were divided into the non-ERAS group (total thoracoscopic mitral valve surgery combined with beating-heart tricuspid annuloplasty without ERAS intervention) and the ERAS group (the same surgical procedures under the concept of ERAS). Propensity score matching (PSM) was used to reduce selection bias. Differences in perioperative blood transfusion, 24-hour postoperative drainage volume, incidence of severe postoperative complications [such as low cardiac output syndrome, liver failure, renal failure, stroke (ischemic/hemorrhagic), perivalvular leakage, re-thoracotomy during hospitalization, etc.], surgery and hospitalization-related indicators (operation time, cardiopulmonary bypass time, aortic cross-clamp time, length of hospital stay, etc.), and echocardiographic results at 1 month after surgery [mitral valve peak pressure difference, mitral valve peak flow velocity, mitral valve pressure half-time (PHT), tricuspid regurgitation area, right ventricular diameter, right atrial diameter] were compared between the two matched groups.Results:After PSM, the selection bias of covariates in the two groups was corrected. There were no statistically significant differences in operation time, cardiopulmonary bypass time, or aortic cross-clamp time between the two groups (all P>0.05). The ICU monitoring time, ventilator use time, and postoperative hospital stay in the ERAS group were significantly shorter than those in the non-ERAS group, with statistically significant differences (all P<0.05). There were no statistically significant differences in 24-hour postoperative drainage volume, perioperative red blood cell transfusion volume, plasma transfusion volume, or total hospitalization cost between the two groups (all P>0.05). Both the ERAS group and the non-ERAS group had 1 case of re-thoracotomy for hemostasis, and the non-ERAS group had 1 case of perivalvular leakage, with no statistically significant differences between the groups ( P>0.05). Echocardiographic results at 1 month after surgery showed that in the ERAS group, tricuspid regurgitation area, right atrial diameter, and right ventricular diameter were significantly improved compared with those before surgery (all P<0.05); in the non-ERAS group, tricuspid regurgitation area was improved compared with that before surgery, with a statistically significant difference ( P<0.05). There were statistically significant differences in the right ventricular diameter and right atrial diameter between the two groups one month after surgery (all P<0.05). Conclusions:Total thoracoscopic mitral valve surgery combined with beating-heart tricuspid valvuloplasty under the intervention of the ERAS concept is safe and effective, but further confirmation from more large-sample clinical studies is needed.

Objective The aim of this study was to detect the expression of miR-383-5p in bladder cancer tissues and bladder cancer 5637 cells,BIU-87 cells,TCCSUP cells and HT-1376 cells,and to explore the effects of miR-383-5p on the prolif-eration,invasion,migration and apoptosis of bladder cancer cells by targeting CIP2A.Methods The expression of miR-383-5p was detected by qRT-PCR in human bladder cancer tissues and their corresponding adjacent tissues,5637 cells,BIU-87 cells,TCCSUP cells,HT-1376 cells,human bladder transitional epithelial cells.BIU-87 cells with low miR-383-5p expression were selected for subsequent experiments.BIU-87 cells were divided into the blank group(normal culture),miR-383-5p NC group(negative control,transfected with miR-383-5p negative control),miR-383-5p mimic group(transfected with miR-383-5p mimic),and miR-383-5p mimic+pc-CIP2A group(co-transfected with miR-383-5p mimic and CIP2A overexpression plasmid pc-CIP2A).CCK-8 kit was used to detect the viability of BIU-87 cells in each group;Flow cytometry was used to detect apoptosis of BIU-87 cells;Transwell assay was used to measure cell invasion ability of BIU-87 cells;Scratch assay was used to measure cell migration ability of BIU-87 cells;Western blot was used to determine the expression of proteins related to apoptosis,invasion(MMP-2,MMP-9),and CIP2A/PP2A in BIU-87 cells;The dual luciferase assay was used to verify the targeting relationship between miR-383-5p and CIP2A in BIU-87 cells.Results The expression of miR-383-5p was low in bladder cancer tissues and bladder cancer cells.Compared with the blank group,BIU-87 cells in the miR-383-5p mimic group showed a significant increase the level of miR-383-5p(0.91±0.10 vs.1.67±0.24,P<0.01)and a significant decrease in the expression of CIP2A protein(1.32±0.17 vs.0.45±0.03,P<0.001),the cell viability,invasion,migration abilities,the expression of proteins related to invasion(MMP-2,MMP-9),and the expression of Bcl-2 protein[(100.00±4.36)% vs.(32.15±2.65)% ,(150.20±12.95)vs.(82.35±7.01),(77.91±3.63)% vs.(46.12±2.54)% ,1.02±0.11 vs.0.22±0.04,1.03±0.18 vs.0.21±0.04,1.01±0.14 vs.0.27±0.05,P<0.001];The apoptosis rate,the expression of caspase-3 and Bax proteins related to apoptosis,and PP2A expression were significantly increased[(14.02±2.29)% vs.(38.21±3.20)% ],0.81±0.11 vs.1.78±0.24,0.83±0.12 vs.1.72±0.24,0.27±0.02 vs.0.95±0.16,P<0.001].Compared with the miR-383-5p mimic group,BIU-87 cells in the miR-383-5p mimic+pc-CIP2A group significantly increased the cell viability,invasion,migration abilities,the expression of proteins related to invasion,and the expression of Bcl-2 protein[(32.15±2.65)% vs.(50.18±3.77)% ,(82.35±7.01)% vs.(116.30±13.70),(46.12±2.54)% vs.(58.43±3.15)% ,0.22±0.04 vs.0.60±0.08,0.21±0.04 vs.0.5 8±0.06,0.27±0.05 vs.0.64±0.08,P<0.05];The apoptosis rate,the expression of caspase-3,Bax,and PP2A was signifi-cantly reduced in the miR-383-5p mimic+pc-CIP2A group[(38.21±3.20)% (23.15±2.74)% ,1.78±0.24 vs.1.25±0.21,1.72±0.24 vs.1.23±0.18,0.95±0.16 vs.0.60±0.13,P<0.05].The results of dual luciferase experiments showed a corresponding tar-geting relationship between miR-383-5p and CIP2A.Conclusion Increasing the expression of miR-383-5p can inhibit the prolif-eration,invasion and migration of bladder cancer BIU-87 cells,and enhance the ability of apoptosis,which may be achieved by targe-ted regulation of CIP2A.

Objective The aim of this study was to detect the expression of miR-383-5p in bladder cancer tissues and bladder cancer 5637 cells,BIU-87 cells,TCCSUP cells and HT-1376 cells,and to explore the effects of miR-383-5p on the prolif-eration,invasion,migration and apoptosis of bladder cancer cells by targeting CIP2A.Methods The expression of miR-383-5p was detected by qRT-PCR in human bladder cancer tissues and their corresponding adjacent tissues,5637 cells,BIU-87 cells,TCCSUP cells,HT-1376 cells,human bladder transitional epithelial cells.BIU-87 cells with low miR-383-5p expression were selected for subsequent experiments.BIU-87 cells were divided into the blank group(normal culture),miR-383-5p NC group(negative control,transfected with miR-383-5p negative control),miR-383-5p mimic group(transfected with miR-383-5p mimic),and miR-383-5p mimic+pc-CIP2A group(co-transfected with miR-383-5p mimic and CIP2A overexpression plasmid pc-CIP2A).CCK-8 kit was used to detect the viability of BIU-87 cells in each group;Flow cytometry was used to detect apoptosis of BIU-87 cells;Transwell assay was used to measure cell invasion ability of BIU-87 cells;Scratch assay was used to measure cell migration ability of BIU-87 cells;Western blot was used to determine the expression of proteins related to apoptosis,invasion(MMP-2,MMP-9),and CIP2A/PP2A in BIU-87 cells;The dual luciferase assay was used to verify the targeting relationship between miR-383-5p and CIP2A in BIU-87 cells.Results The expression of miR-383-5p was low in bladder cancer tissues and bladder cancer cells.Compared with the blank group,BIU-87 cells in the miR-383-5p mimic group showed a significant increase the level of miR-383-5p(0.91±0.10 vs.1.67±0.24,P<0.01)and a significant decrease in the expression of CIP2A protein(1.32±0.17 vs.0.45±0.03,P<0.001),the cell viability,invasion,migration abilities,the expression of proteins related to invasion(MMP-2,MMP-9),and the expression of Bcl-2 protein[(100.00±4.36)% vs.(32.15±2.65)% ,(150.20±12.95)vs.(82.35±7.01),(77.91±3.63)% vs.(46.12±2.54)% ,1.02±0.11 vs.0.22±0.04,1.03±0.18 vs.0.21±0.04,1.01±0.14 vs.0.27±0.05,P<0.001];The apoptosis rate,the expression of caspase-3 and Bax proteins related to apoptosis,and PP2A expression were significantly increased[(14.02±2.29)% vs.(38.21±3.20)% ],0.81±0.11 vs.1.78±0.24,0.83±0.12 vs.1.72±0.24,0.27±0.02 vs.0.95±0.16,P<0.001].Compared with the miR-383-5p mimic group,BIU-87 cells in the miR-383-5p mimic+pc-CIP2A group significantly increased the cell viability,invasion,migration abilities,the expression of proteins related to invasion,and the expression of Bcl-2 protein[(32.15±2.65)% vs.(50.18±3.77)% ,(82.35±7.01)% vs.(116.30±13.70),(46.12±2.54)% vs.(58.43±3.15)% ,0.22±0.04 vs.0.60±0.08,0.21±0.04 vs.0.5 8±0.06,0.27±0.05 vs.0.64±0.08,P<0.05];The apoptosis rate,the expression of caspase-3,Bax,and PP2A was signifi-cantly reduced in the miR-383-5p mimic+pc-CIP2A group[(38.21±3.20)% (23.15±2.74)% ,1.78±0.24 vs.1.25±0.21,1.72±0.24 vs.1.23±0.18,0.95±0.16 vs.0.60±0.13,P<0.05].The results of dual luciferase experiments showed a corresponding tar-geting relationship between miR-383-5p and CIP2A.Conclusion Increasing the expression of miR-383-5p can inhibit the prolif-eration,invasion and migration of bladder cancer BIU-87 cells,and enhance the ability of apoptosis,which may be achieved by targe-ted regulation of CIP2A.

Objective:To summarize and compare the clinical characteristics of immune checkpoint inhibitor-associated pneumonia(CIP)in elderly and non-elderly lung cancer patients treated with immune checkpoint inhibitors(ICIs).Methods:We conducted a retrospective analysis of the clinical data from 61 patients who developed CIP following ICIs treatment in the Respiratory and Critical Care Medicine Department and the Oncology Department of Beijing Hospital from May 2016 to April 2024.The clinical characteristics of patients aged 65 years and older were compared with those of patients younger than 65 years.Results:A total of 61 patients were included in the study, with 26 patients in the group aged <65 years[aged 39-64(56.3±5.6)years].Within this group, the clinical grades were distributed as follows: 5 patients in grade 1(G1), 12 in grade 2(G2), 7 in grade 3(G3), and 2 in grade 4(G4).Twelve patients underwent bronchoscopy, while 17 patients received corticosteroid therapy after developing CIP.Additionally, 20 patients permanently discontinued immunotherapy due to CIP.Notably, one patient showed improvement in CIP following treatment, which allowed for the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.In the group aged ≥65 years[aged 65-83(71.9±4.9)years], there were 35 patients, categorized as follows: 4 in G1, 22 in G2, 5 in G3, and 4 in G4.Twenty-one patients underwent bronchoscopy, 31 received corticosteroid therapy after developing CIP, and 30 patients permanently discontinued immunotherapy due to CIP.Similarly, one patient in this group demonstrated improvement in CIP following treatment, which permitted the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.Compared to patients aged <65 years, those aged ≥65 years experienced a shorter median time to the occurrence of CIP, with a median of 2(1, 4)months versus 5.5(2, 8)months for the younger group( Z=-3.231, P=0.001).Furthermore, a higher proportion of patients aged ≥65 years received corticosteroid therapy after developing CIP(88.57% or 31 cases)compared to 65.38%(17 cases)in the younger group( χ2=4.704, P=0.030).There were no statistically significant differences in the occurrence of CIP symptoms or chest imaging characteristics between the two age groups(both P>0.05). Conclusions:Patients aged 65 years and older experience a shorter median time to develop CIP following the use of ICIs.However, there is no significant difference in clinical outcomes when compared to the group aged under 65 years, provided that early identification and diagnosis are achieved.

Objective:To summarize the clinical characteristics of SAPHO syndrome in elderly patients with organizing pneumonia.Methods:We reported a case of SAPHO syndrome in an elderly patient with organizing pneumonia.Relevant reports on SAPHO syndrome with organizing pneumonia at home and abroad were retrieved, and the literature was summarized an analyzed.Results:The patient was a 63-year-od female who was admitted to the hospital due to "intermittent fever and cough for more than two months". Before admission, she was previously diagnosed with pneumonia in another hospital with poor response to anti-infective treatment.Chest CT showed multiple bilateral patchy consolidations in both lungs, with migratory changes and reversed halo signs.Her medical history included bone and joint pain(e.g., sternoclavicular joints)and palmoplantar pustulosis.Lung biopsy pathology confirmed organizing pneumonia. 99mTc-MDP bone scintigraphy revealed abnormal bone salt metabolism in multiple bone and joint areas.The final diagnosis was SAPHO syndrome with organizing pneumonia.Both symptoms and imaging significantly improved after prednisone treatment.Two related cases were retrieved from the literature.One was a 57-year-old female reported in the UK, who had been diagnosed with SAPHO syndrome before and was found to have lung consolidations due to respiratory symptoms.Lung biopsy confirmed organizing pneumonia, and she improved after glucocorticoid treatment.The other was a 59-year-old Chinese female who visited hospital due to pain in the lumbosacral part and left lower limb.After being diagnosed with SAPHO syndrome, a chest CT scan was performed and lung consolidations were found.The pathology confirmed organizing pneumonia.The patient improved after treatment with Tripterygium wilfordii. Conclusion:SAPHO syndrome complicated with organizing pneumonia is rare, with diverse clinical manifestations, and responds well to glucocorticoid therapy.

Objective:To evaluate the clinical efficacy of total thoracoscopic mitral valve surgery combined with beating-heart tricuspid valvuloplasty under the concept of enhanced recovery after surgery (ERAS).Methods:Clinical data from the People′s Hospital of Guangxi Zhuang Autonomous Region from January 2012 to January 2024 were collected and analyzed retrospectively. Patients were divided into the non-ERAS group (total thoracoscopic mitral valve surgery combined with beating-heart tricuspid annuloplasty without ERAS intervention) and the ERAS group (the same surgical procedures under the concept of ERAS). Propensity score matching (PSM) was used to reduce selection bias. Differences in perioperative blood transfusion, 24-hour postoperative drainage volume, incidence of severe postoperative complications [such as low cardiac output syndrome, liver failure, renal failure, stroke (ischemic/hemorrhagic), perivalvular leakage, re-thoracotomy during hospitalization, etc.], surgery and hospitalization-related indicators (operation time, cardiopulmonary bypass time, aortic cross-clamp time, length of hospital stay, etc.), and echocardiographic results at 1 month after surgery [mitral valve peak pressure difference, mitral valve peak flow velocity, mitral valve pressure half-time (PHT), tricuspid regurgitation area, right ventricular diameter, right atrial diameter] were compared between the two matched groups.Results:After PSM, the selection bias of covariates in the two groups was corrected. There were no statistically significant differences in operation time, cardiopulmonary bypass time, or aortic cross-clamp time between the two groups (all P>0.05). The ICU monitoring time, ventilator use time, and postoperative hospital stay in the ERAS group were significantly shorter than those in the non-ERAS group, with statistically significant differences (all P<0.05). There were no statistically significant differences in 24-hour postoperative drainage volume, perioperative red blood cell transfusion volume, plasma transfusion volume, or total hospitalization cost between the two groups (all P>0.05). Both the ERAS group and the non-ERAS group had 1 case of re-thoracotomy for hemostasis, and the non-ERAS group had 1 case of perivalvular leakage, with no statistically significant differences between the groups ( P>0.05). Echocardiographic results at 1 month after surgery showed that in the ERAS group, tricuspid regurgitation area, right atrial diameter, and right ventricular diameter were significantly improved compared with those before surgery (all P<0.05); in the non-ERAS group, tricuspid regurgitation area was improved compared with that before surgery, with a statistically significant difference ( P<0.05). There were statistically significant differences in the right ventricular diameter and right atrial diameter between the two groups one month after surgery (all P<0.05). Conclusions:Total thoracoscopic mitral valve surgery combined with beating-heart tricuspid valvuloplasty under the intervention of the ERAS concept is safe and effective, but further confirmation from more large-sample clinical studies is needed.

Objective:To compare the surgical efficacy of pericardial soft ring tricuspid valvuloplasty with DeVega and artificial valvuloplasty.Methods:227 patients undergoing tricuspid valvuloplasty due to rheumatic heart disease complicated with functional tricuspid valve insufficiency were retrospectively analyzed and divided into 3 groups according to tricuspid valvuloplasty dynamic cohort(pericardial ring group, 89 cases; the artificial flap ring group, 61 cases, and the DeVega group, 77 cases) were matched 1∶1 for propensity score(match A: pericardial ring group and artificial flap ring group; match B: pericardial ring group and DeVega group), the successful matching was included in follow-up and data collection, and cases with incomplete case data during follow-up were removed from the study cohort in pairs according to matching conditions. The results of follow-up 1 month, 6 months and 24 months after surgery were compared.Results:1 month after operation: the tricuspid valve regurgitant in all groups was significantly reduced or even disappeared compared with that before operation, and the right atrium and right ventricle were also smaller than that before operation, with statistical significance( P<0.05). 6 months after surgery: There was no statistical significance in the area of tricuspid regurgitation and right atrial/indoor diameter between all groups compared with the results one month after surgery( P>0.05), and there was no statistical significance in the recurrence rate of tricuspid regurgitation between all groups( P>0.05). 24 months after surgery: There were no significant differences in the recurrence rate of tricuspid regurgitation, area of tricuspid regurgitation and right atrial/indoor diameter between the two groups in matching A( P>0.05). There was no statistical significance in the right atrial/indoor diameter between the matched pericardial ring group and the Devega group, but the tricuspid valve regurgentation area of the Devega group at 24 months after surgery was higher than that of the Devega group at 1 month after surgery, and the difference was statistically significant( P<0.05). The regurgitation area and recurrence rate of tricuspid valve were significantly higher than those of pericardium-TVP group( P<0.05). Conclusion:Pericardial soft ring tricuspid valvuloplasty can effectively correct functional tricuspid valvuloplasty and reverse right heart remodeling, which is an effective tricuspid valvuloplasty.

Objective:To explore the clinical characteristics of patients with pulmonary sarcoidosis complicated by pulmonary cryptococcosis, thereby enhancing the understanding of this clinical scenario.Methods:We report a case of pulmonary sarcoidosis complicated by pulmonary cryptococcosis treated at Beijing Hospital.The patient was diagnosed with stage Ⅱ pulmonary sarcoidosis via CT-guided percutaneous fine needle aspiration lung biopsy.However, during treatment with oral prednisone, a chest CT scan revealed newly developed multiple nodules in the right lower lobe.By considering the patient's medical history, imaging results, cryptococcal antigen(CrAg)levels, and treatment response, a diagnosis of pulmonary sarcoidosis complicated by pulmonary cryptococcosis was established.Additionally, we systematically reviewed the literature on pulmonary sarcoidosis complicated by pulmonary cryptococcosis published before April 2024, focusing on epidemiological characteristics, clinical manifestations, diagnosis, treatment, and prognosis.Results:A total of seven articles were obtained, and nine cases were reviewed in conjunction with this case.Among these, 55.6%(5/9)of the patients were male, with an average age of 51 years, and one-third of the patients were categorized as elderly.The stages of pulmonary sarcoidosis identified were stage Ⅰ and stage Ⅱ.Eight patients(88.9%, 8/9)were receiving glucocorticoids or other immunosuppressants at the time of cryptococcosis diagnosis.In the cases that specified the diagnostic method for cryptococcosis, serum cryptococcal antigen(CrAg)was found to be positive, including in three elderly patients.One patient did not receive antifungal treatment due to the rapid deterioration of his condition.During a follow-up period of at least six months, all patients remained clinically stable, with fluconazole being the most chosen antifungal agent.Conclusions:Although cases of pulmonary sarcoidosis complicated by cryptococcal infection are rare, clinicians should remain vigilant to this possibility.The two conditions may exhibit overlapping clinical manifestations, yet their treatment strategies can be contradictory.Misdiagnosis and delayed diagnosis could result in serious clinical consequences.Serum CrAg testing is particularly useful for diagnosis, especially in elderly patients.